NOW APPROVED

THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR EoE1

DUPIXENT is indicated for the treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE).

DUPIXENT is a biologic that inhibits IL-4 and IL-13 signaling, two key drivers of underlying type 2 inflammation in EoE.1,2

The mechanism of dupilumab action has not been definitively established.

DUPIXENT is not an immunosuppressant1

Support can make all the difference. DUPIXENT MyWay® is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.

Learn how we can help

DUPIXENT MyWay
ENROLLMENT FORMS

FOR GASTROENTEROLOGISTS
English Enrollment Form
Spanish Enrollment Form
FOR ALLERGISTS
Allergist (EoE) English Enrollment Form
Allergist (EoE) Spanish Enrollment Form

Many Patients. One DUPIXENT.1

ATOPIC DERMATITIS

6+ MONTHS OF AGE
Uncontrolled moderate-to-severe

ASTHMA

6+ YEARS OF AGE
Eosinophilic phenotype or OCS-dependent

CRSwNP

18+ YEARS OF AGE
Inadequately controlled

EOSINOPHILIC ESOPHAGITIS

12+ YEARS OF AGE
Weighing at least 40 kg

 CRSwNP, chronic rhinosinusitis with nasal polyposis; OCS, oral corticosteroids.

References:

  1. DUPIXENT Prescribing Information.
  2. Bredenoord AJ, Patel K, Schoepfer AM, et al. Disease burden and unmet need in eosinophilic esophagitis. Am J Gastroenterol. Published online April 13, 2022. doi:10.14309/ajg.0000000000001777